Answers are grounded in this paper and cite their sources.
This analysis highlights immune requirements affecting the durability of next-generation cellular therapies in solid tumors, suggesting new insights.
Background Next-generation cellular therapies, including CAR-T cells and T cell engagers, have produced transformative outcomes in hematologic malignancies but continue to show limited durability in solid tumors. These failures are commonly attributed to antigen heterogeneity, immune suppression, trafficking barriers, or manufacturing constraints. While each factor contributes, this framing often treats failure as multifactorial complexity rather than as a consequence of unmet or misordered immune requirements.
No takes yet. Share an insight, caveat, or question.
Kate Lynn Blatt (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: